NASDAQ:XCUR Exicure (XCUR) Stock Price, News & Analysis → World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad) Free XCUR Stock Alerts $0.51 0.00 (-0.50%) (As of 01:01 PM ET) Add Compare Share Share Today's Range$0.51▼$0.5250-Day Range$0.52▼$0.7452-Week Range$0.36▼$1.50Volume13,985 shsAverage Volume382,495 shsMarket Capitalization$4.43 millionP/E Ratio0.31Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Exicure alerts: Email Address Exicure MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.01% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.24Based on 3 Articles This WeekInsider TradingSelling Shares$4.49 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.11 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Exicure. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.01% of the float of Exicure has been sold short.Short Interest Ratio / Days to CoverExicure has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exicure has recently decreased by 16.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldExicure does not currently pay a dividend.Dividend GrowthExicure does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExicure has received a 74.39% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Clinical research services for cancer", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Exicure is -0.67. Previous Next 1.8 News and Social Media Coverage News SentimentExicure has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Exicure this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exicure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,488,000.00 in company stock.Percentage Held by InsidersOnly 3.90% of the stock of Exicure is held by insiders.Percentage Held by Institutions42.82% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Exicure is 0.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 140.00.Price to Earnings Ratio vs. SectorThe P/E ratio of Exicure is 0.31, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 194.35.Price to Book Value per Share RatioExicure has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Exicure Stock (NASDAQ:XCUR)Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.Read More XCUR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XCUR Stock News HeadlinesApril 24, 2024 | investing.comExicure faces Nasdaq non-compliance over delayed filingApril 22, 2024 | businesswire.comExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-KApril 25, 2024 | American Hartford Gold Group (Ad)Rich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.April 18, 2024 | americanbankingnews.comExicure (NASDAQ:XCUR) Shares Down 8.7% February 22, 2024 | benzinga.comExicure Stock (NASDAQ:XCUR), Short Interest ReportFebruary 6, 2024 | benzinga.comWhy FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionFebruary 6, 2024 | msn.comWhy Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving PremarketFebruary 6, 2024 | msn.comExicure Inc Announces Licensing Patents for Therapeutic AdvancementApril 25, 2024 | American Hartford Gold Group (Ad)Rich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.February 5, 2024 | marketwatch.comExicure, Bluejay Therapeutics Enter Patent License Agreement to Develop Hepatitis TreatmentFebruary 5, 2024 | finance.yahoo.comExicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of HepatitisFebruary 1, 2024 | msn.comBest Undervalued Stocks for February 2024December 16, 2023 | ca.finance.yahoo.comExicure, Inc. (XCUR) Stock Price, News, Quote & History - Yahoo FinanceDecember 8, 2023 | investorplace.comWhy Is Exicure (XCUR) Stock Up 57% Today?November 28, 2023 | msn.comExicure receives Nasdaq delinquency notice on late filing of its form 10-QNovember 9, 2023 | morningstar.comExicure Inc XCURAugust 29, 2023 | finance.yahoo.comLacklustre Performance Is Driving Exicure, Inc.'s (NASDAQ:XCUR) 25% Price DropAugust 23, 2023 | msn.comExicure names new CEO, CFO, directors in wake of resignationsAugust 15, 2023 | finance.yahoo.comExicure First Half 2023 Earnings: US$1.38 loss per share (vs US$3.71 loss in 1H 2022)August 11, 2023 | marketwatch.comExicure: Substantial Financing Needed to Continue OperationsAugust 11, 2023 | businesswire.comExicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 14, 2023 | finance.yahoo.comExicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 26, 2023 | msn.comExicure board backs CEO Kim's strategic alternative view for companyMay 26, 2023 | finance.yahoo.comExicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic AlternativesMay 25, 2023 | sg.finance.yahoo.comExicure, Inc. (XCUR) stock price, news, quote & history – Yahoo FinanceMay 19, 2023 | seekingalpha.comExicure gets Nasdaq non-compliance notice for not filing 10-QApril 27, 2023 | finance.yahoo.comExicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of DirectorsSee More Headlines Receive XCUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exicure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/19/2021Today4/25/2024Next Earnings (Estimated)7/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XCUR CUSIPN/A CIK1698530 Webwww.exicuretx.com Phone(847) 673-1700FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.31 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$28.83 million Price / Sales0.15 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book0.17Miscellaneous Outstanding Shares8,650,000Free Float8,311,000Market Cap$4.45 million OptionableNot Optionable Beta1.31 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Paul Kang (Age 62)CEO & Director Ms. Jiyoung Hwang (Age 47)CFO & Director Mr. Joshua Miller (Age 48)Chief Accounting Officer Mr. Bart AndersonSenior Director of R&DKey CompetitorsPetros PharmaceuticalsNASDAQ:PTPINexImmuneNASDAQ:NEXIProcessa PharmaceuticalsNASDAQ:PCSALongeveronNASDAQ:LGVNChina PharmaNYSE:CPHIView All CompetitorsInsidersCo. Ltd. DgpSold 3,400,000 sharesTotal: $4.49 M ($1.32/share)View All Insider Transactions XCUR Stock Analysis - Frequently Asked Questions How have XCUR shares performed in 2024? Exicure's stock was trading at $0.5803 at the beginning of the year. Since then, XCUR stock has decreased by 11.7% and is now trading at $0.5124. View the best growth stocks for 2024 here. Are investors shorting Exicure? Exicure saw a decrease in short interest in April. As of April 15th, there was short interest totaling 151,700 shares, a decrease of 16.0% from the March 31st total of 180,600 shares. Based on an average daily trading volume, of 213,100 shares, the days-to-cover ratio is currently 0.7 days. Currently, 2.0% of the shares of the company are sold short. View Exicure's Short Interest. When is Exicure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, July 12th 2024. View our XCUR earnings forecast. How were Exicure's earnings last quarter? Exicure, Inc. (NASDAQ:XCUR) posted its earnings results on Friday, November, 19th. The company reported ($8.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.70) by $5.40. The company earned ($3.68) million during the quarter, compared to analysts' expectations of $0.80 million. When did Exicure's stock split? Exicure's stock reverse split on the morning of Thursday, June 30th 2022. The 1-30 reverse split was announced on Thursday, June 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Exicure? Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XCUR) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
